Cargando…

A case of hemophagocytic lymphohistiocytosis after BNT162b2 COVID-19 (Comirnaty®) vaccination

Coronavirus disease (COVID-19), an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 virus, was reported in Wuhan of China in December 2019. The world is still in a state of pandemic owing to COVID-19. COVID-19 vaccines help our bodies develop immunity against the viru...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimada, Yoshitaka, Nagaba, Yasushi, Okawa, Hiroyuki, Ehara, Kaori, Okada, Shinya, Yokomori, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622336/
https://www.ncbi.nlm.nih.gov/pubmed/36316859
http://dx.doi.org/10.1097/MD.0000000000031304
_version_ 1784821743681011712
author Shimada, Yoshitaka
Nagaba, Yasushi
Okawa, Hiroyuki
Ehara, Kaori
Okada, Shinya
Yokomori, Hiroaki
author_facet Shimada, Yoshitaka
Nagaba, Yasushi
Okawa, Hiroyuki
Ehara, Kaori
Okada, Shinya
Yokomori, Hiroaki
author_sort Shimada, Yoshitaka
collection PubMed
description Coronavirus disease (COVID-19), an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 virus, was reported in Wuhan of China in December 2019. The world is still in a state of pandemic owing to COVID-19. COVID-19 vaccines help our bodies develop immunity against the virus that causes COVID-19 without having to get the illness. Herein, we describe a rare case of a critical disorder, hemophagocytic lymphohistiocytosis (HLH), in a patient with nephritic sclerosis associated with hypertension, following mRNA COVID-19 vaccination. HLH is a life-threatening hyperinflammatory syndrome caused by aberrantly activated macrophages and cytotoxic T cells that may rapidly progress to terminal multiple organ failure. PATIENT CONCERNS: An 85-year-old Japanese woman with chronic renal failure and hypertension was included in this study. Routine laboratory investigations provided the following results: white blood cell (WBC) count, 4.6 × 10(9)/L; hemoglobin (Hb), 8.1 g/dL; platelet count, 27 × 10(9)/L; blood urea nitrogen 48.9 mg/dL, and serum creatinine 3.95 mg/dL. The patient developed malaise, vomiting, and persistent high fever (up to 39.7°C) on the 12(th) day after receiving the second dose of the vaccine. Initial evaluation revealed neutropenia. The total WBC count was 0.40 × 10(9)/L (Neutrophils 0, Lymphocytes 240/μ, blast 0%); Hb 9.0 g/dL, platelet count 27 × 10(9)/L; and, C Reactive Protein 9.64 mg/dL. DIAGNOSIS: Further tests showed hyperferritinemia (serum ferritin 2284.4 μg/L). Bone marrow examination revealed haemophagocytosis. A provisional diagnosis of HLH associated with the Comirnaty(®) vaccination was made based on the HLH-2004 diagnostic criteria. INTERVENTIONS: The patient was treated with granulocyte colony-stimulating factor and 500 mg methylprednisolone. OUTCOMES: A significant improvement was observed in the patient’s condition; the abnormal laboratory results resolved gradually, and the patient was discharged. LESSONS: This case serves to create awareness among clinicians that HLH is a rare complication of COVID-19 vaccination and should be considered, especially in patients with a history of chronic renal failure and hypertension.
format Online
Article
Text
id pubmed-9622336
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-96223362022-11-01 A case of hemophagocytic lymphohistiocytosis after BNT162b2 COVID-19 (Comirnaty®) vaccination Shimada, Yoshitaka Nagaba, Yasushi Okawa, Hiroyuki Ehara, Kaori Okada, Shinya Yokomori, Hiroaki Medicine (Baltimore) 4800 Coronavirus disease (COVID-19), an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 virus, was reported in Wuhan of China in December 2019. The world is still in a state of pandemic owing to COVID-19. COVID-19 vaccines help our bodies develop immunity against the virus that causes COVID-19 without having to get the illness. Herein, we describe a rare case of a critical disorder, hemophagocytic lymphohistiocytosis (HLH), in a patient with nephritic sclerosis associated with hypertension, following mRNA COVID-19 vaccination. HLH is a life-threatening hyperinflammatory syndrome caused by aberrantly activated macrophages and cytotoxic T cells that may rapidly progress to terminal multiple organ failure. PATIENT CONCERNS: An 85-year-old Japanese woman with chronic renal failure and hypertension was included in this study. Routine laboratory investigations provided the following results: white blood cell (WBC) count, 4.6 × 10(9)/L; hemoglobin (Hb), 8.1 g/dL; platelet count, 27 × 10(9)/L; blood urea nitrogen 48.9 mg/dL, and serum creatinine 3.95 mg/dL. The patient developed malaise, vomiting, and persistent high fever (up to 39.7°C) on the 12(th) day after receiving the second dose of the vaccine. Initial evaluation revealed neutropenia. The total WBC count was 0.40 × 10(9)/L (Neutrophils 0, Lymphocytes 240/μ, blast 0%); Hb 9.0 g/dL, platelet count 27 × 10(9)/L; and, C Reactive Protein 9.64 mg/dL. DIAGNOSIS: Further tests showed hyperferritinemia (serum ferritin 2284.4 μg/L). Bone marrow examination revealed haemophagocytosis. A provisional diagnosis of HLH associated with the Comirnaty(®) vaccination was made based on the HLH-2004 diagnostic criteria. INTERVENTIONS: The patient was treated with granulocyte colony-stimulating factor and 500 mg methylprednisolone. OUTCOMES: A significant improvement was observed in the patient’s condition; the abnormal laboratory results resolved gradually, and the patient was discharged. LESSONS: This case serves to create awareness among clinicians that HLH is a rare complication of COVID-19 vaccination and should be considered, especially in patients with a history of chronic renal failure and hypertension. Lippincott Williams & Wilkins 2022-10-28 /pmc/articles/PMC9622336/ /pubmed/36316859 http://dx.doi.org/10.1097/MD.0000000000031304 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 4800
Shimada, Yoshitaka
Nagaba, Yasushi
Okawa, Hiroyuki
Ehara, Kaori
Okada, Shinya
Yokomori, Hiroaki
A case of hemophagocytic lymphohistiocytosis after BNT162b2 COVID-19 (Comirnaty®) vaccination
title A case of hemophagocytic lymphohistiocytosis after BNT162b2 COVID-19 (Comirnaty®) vaccination
title_full A case of hemophagocytic lymphohistiocytosis after BNT162b2 COVID-19 (Comirnaty®) vaccination
title_fullStr A case of hemophagocytic lymphohistiocytosis after BNT162b2 COVID-19 (Comirnaty®) vaccination
title_full_unstemmed A case of hemophagocytic lymphohistiocytosis after BNT162b2 COVID-19 (Comirnaty®) vaccination
title_short A case of hemophagocytic lymphohistiocytosis after BNT162b2 COVID-19 (Comirnaty®) vaccination
title_sort case of hemophagocytic lymphohistiocytosis after bnt162b2 covid-19 (comirnaty®) vaccination
topic 4800
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622336/
https://www.ncbi.nlm.nih.gov/pubmed/36316859
http://dx.doi.org/10.1097/MD.0000000000031304
work_keys_str_mv AT shimadayoshitaka acaseofhemophagocyticlymphohistiocytosisafterbnt162b2covid19comirnatyvaccination
AT nagabayasushi acaseofhemophagocyticlymphohistiocytosisafterbnt162b2covid19comirnatyvaccination
AT okawahiroyuki acaseofhemophagocyticlymphohistiocytosisafterbnt162b2covid19comirnatyvaccination
AT eharakaori acaseofhemophagocyticlymphohistiocytosisafterbnt162b2covid19comirnatyvaccination
AT okadashinya acaseofhemophagocyticlymphohistiocytosisafterbnt162b2covid19comirnatyvaccination
AT yokomorihiroaki acaseofhemophagocyticlymphohistiocytosisafterbnt162b2covid19comirnatyvaccination
AT shimadayoshitaka caseofhemophagocyticlymphohistiocytosisafterbnt162b2covid19comirnatyvaccination
AT nagabayasushi caseofhemophagocyticlymphohistiocytosisafterbnt162b2covid19comirnatyvaccination
AT okawahiroyuki caseofhemophagocyticlymphohistiocytosisafterbnt162b2covid19comirnatyvaccination
AT eharakaori caseofhemophagocyticlymphohistiocytosisafterbnt162b2covid19comirnatyvaccination
AT okadashinya caseofhemophagocyticlymphohistiocytosisafterbnt162b2covid19comirnatyvaccination
AT yokomorihiroaki caseofhemophagocyticlymphohistiocytosisafterbnt162b2covid19comirnatyvaccination